Moderna to Pay Arbutus $950M in LNP Patent Settlement, Potential $1.3B More
ABUS sits 88% above its 52-week low of $2.705 on elevated volume (2.2× avg).
Summary
Arbutus Biopharma has reached a global settlement and license agreement with Moderna, resolving disputes over lipid nanoparticle (LNP) technology. Moderna will make an initial payment of $950 million by July 8, 2026, with the potential for an additional $1.3 billion depending on the outcome of a pending appeal. This settlement follows a U.S. District Court order in February that rejected Moderna's arguments in the patent infringement lawsuit, culminating a significant legal battle. The initial payment, of which Arbutus is entitled to 20% after litigation costs, represents a highly material cash infusion, significantly bolstering the company's financial position and removing a major legal overhang. Investors will now focus on the appeal's outcome and Arbutus's strategic use of these substantial proceeds.
At the time of this announcement, ABUS was trading at $5.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $902M. The 52-week trading range was $2.71 to $5.10. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Wiseek News.